Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 8;13(1):89.
doi: 10.1186/s13048-020-00693-w.

Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications

Affiliations

Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications

Wei Chen et al. J Ovarian Res. .

Abstract

Background: This study attempts to evaluate whether preoperative systemic inflammatory response (SIR) markers or other hematological variables, such as albumin, D-dimer, and carbohydrate antigen 125, play roles in predicting chemotherapy response and survival outcome in patients with ovarian clear cell carcinoma (OCCC).

Methods: Preoperative leukocyte differential counts, as well as platelet, serum albumin, plasma D-dimer and CA-125 levels, were measured in patients with FIGO IC-IV ovarian clear cell cancer. The correlations of these hematological biomarkers with clinicopathological features, chemotherapy response, and survival outcomes were further analyzed. Survival time was estimated using the Kaplan-Meier model, whereas Cox regression was conducted for multivariate analysis.

Results: Among the 84 patients, 28.6% were classified as platinum resistant, and 69.0% were platinum sensitive. Preoperative CA125, albumin, and D-dimer levels; neutrophil to lymphocyte ratios (NLR); and monocyte to lymphocyte ratios were significantly correlated with FIGO stage, residual tumor, and platinum response. Platelet to lymphocyte ratio was not related to platinum response (P = 0.060). The median follow-up time was 28 months (range, 1 to 128 months). Preoperative CA125, albumin, and D-dimer levels were significant prognostic factors for overall survival (OS) and progression-free survival (PFS). In the univariate analysis, only NLR exhibited prognostic significance for PFS (P = 0.007). Multivariate analysis indicated that D-dimer > 3.27 (P = 0.001 for OS; P = 0.040 for PFS) and albumin < 39.6 (P = 0.005 for OS and P = 0.041 for PFS) retained significance.

Conclusions: Preoperative NLR has some predictive value for platinum resistance in patients with IC-IV stage OCCC but has little predictive effect on prognosis. Elevated D-dimer and reduced albumin might be potential biomarkers for worse response to first-line platinum-based chemotherapy and poor clinical outcomes.

Keywords: Albumin; Clear cell carcinoma; D-dimer; Neutrophil to lymphocyte ratio; Ovarian neoplasms; Platinum resistance; Recurrence; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Receiver operating characteristic curve demonstrating the AUC of preoperative MLR, NLR, CA125, D2, and ALB for platinum resistance. (Abbreviations: AUC, the area under the curve; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; CA125, carbohydrate antigen 125; D2, D-dimer; ALB, albumin)
Fig. 2
Fig. 2
Kaplan-Meier curves showing PFS and OS stratified by preoperative ALB (a), D2 (b), and groups combining ALB and D2 (c). Group 1, high ALB/low D2; group 2, high ALB/high D2 and low ALB/low D2; group 3, low ALB/high D2. The p-values were calculated using the log-rank test. (Abbreviations: ALB, albumin; D2, D-dimer; PFS, progression-free survival; OS, overall survival)
Fig. 3
Fig. 3
The risk of disease progression and death compared to ALB-high and D2-low. (Abbreviations: ALB, albumin; D2, D-dimer)

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Anglesio MS, Carey MS, Köbel M, Mackay H, Huntsman DG. Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, June 24th, 2010. Gynecol Oncol. 2011;121(2):407–415. doi: 10.1016/j.ygyno.2011.01.005. - DOI - PubMed
    1. Glasspool RM, McNeish IA. Clear cell carcinoma of ovary and uterus. Curr Oncol Rep. 2013;15(6):566–572. doi: 10.1007/s11912-013-0346-0. - DOI - PubMed
    1. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012;126(3):481–490. doi: 10.1016/j.ygyno.2012.04.021. - DOI - PubMed
    1. Bennett JA, Dong F, Young RH, Oliva E. Clear cell carcinoma of the ovary: evaluation of prognostic parameters based on a clinicopathological analysis of 100 cases. Histopathology. 2015;66(6):808–815. doi: 10.1111/his.12514. - DOI - PubMed

MeSH terms